BridgeBio's Acoramidis Shows Stronger Disease-Modifying Effects in ATTR-CM Than Competitor
Event summary
- Acoramidis significantly reduced sTTR variability versus placebo (p<0.001), associated with reduced all-cause mortality in ATTR-CM.
- Acoramidis demonstrated a 41% reduction in outpatient worsening heart failure risk within 30 days, sustained through Month 30.
- Matching-adjusted indirect comparison showed acoramidis reduced cardiovascular hospitalizations by 34% versus tafamidis.
- Acoramidis maintained a comparable safety profile to tafamidis with a favorable mortality trend.
The big picture
BridgeBio's acoramidis is positioning itself as a potential leader in the ATTR-CM treatment landscape, with data suggesting superior disease-modifying effects compared to existing therapies. The focus on reducing sTTR variability and early intervention in heart failure progression aligns with broader industry trends toward precision medicine in genetic conditions. The company's decentralized model aims to accelerate bringing such specialized treatments to market, though competition and regulatory hurdles remain significant.
What we're watching
- Clinical Differentiation
- Whether acoramidis' demonstrated superiority in reducing sTTR variability and outpatient worsening heart failure will translate into market share gains against tafamidis.
- Regulatory Expansion
- The pace at which BridgeBio can secure additional approvals for acoramidis in new markets, leveraging its partnership with Bayer in Europe.
- Long-Term Efficacy
- How sustained the clinical benefits of acoramidis will be over extended follow-up periods, particularly in advanced ATTR-CM patients.